|
Bone Biologics Corporation (NASDAQ: BBLG) |
|
Bone Biologics Corporation
BBLG's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Bone Biologics's sales fell
in the fourth quarter of 2024 from the same quarter a year ago.
Medical Equipment & Supplies industry recorded
deterioration of revenues by -0.09 %
Bone Biologics net loss decreased from $-4 millions, to $-2 millions in fourth quarter of 2024,
• More on BBLG's Growth
|
|
Bone Biologics realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 26.92 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.06.
• More on BBLG's Valuation
|
|
|
|
|
Bone Biologics realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 26.92 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.06.
Bone Biologics Price to Book Ratio is at 2.31 higher than Industry Avg. of -499.95, and higher than S&P 500 Avg. of 0.01
• More on BBLG's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com